Individualized Chemotherapy for Patients with Non-Small Cell Lung Cancer Determined by Prospective Identification of Neuroendocrine Markers and in Vitro Drug Sensitivity Testing

摘要: Abstract We attempted to prospectively select individualized chemotherapy for 165 non-small cell lung cancer patients based on in vitro analysis of neuroendocrine (NE) markers and drug sensitivity testing (DST) using fresh tumor. The used small (SCLC) was selected when NE marker expression determined by l-dopa decarboxylase assay documented. Selection other guided DST results a modified dye exclusion available; otherwise etoposide cisplatin administered. A total 112 (68%) specimens were assayed 36 (22%) had DST. In data directed management 27 96 (28%) given chemotherapy: 6 with treated the SCLC regimen; 21 (58% those DST) received their DST-selected regimen. There no significant differences response rate among all 3 treatment arms ( P = 0.076). However, regimen (50%), marginally better than (2 21; 9%; 0.056) or (10 69; 14%; 0.061). When whose identified retrospectively are included, 4 9 (44%) responded administered chemotherapy, compared 7 55 (13%) present 0.04). survival three groups. Cisplatin comprised most active tumors from 16 patients, potentially limiting benefit since this is often empiric therapy non-SCLC. Furthermore, correlation between clinical nonsignificant drugs tested, highlighting overall relative resistance non-SCLC currently available chemotherapy.